Generation of highly purified human cardiomyocytes from peripheral blood mononuclear cell-derived induced pluripotent stem cells
Induced pluripotent stem (iPS) cells have an enormous potential for physiological studies. A novel protocol was developed combining the derivation of iPS from peripheral blood with an optimized directed differentiation to cardiomyocytes and a subsequent metabolic selection. The human iPS cells were...
Saved in:
Published in: | PloS one Vol. 10; no. 5; p. e0126596 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
Public Library of Science
13-05-2015
Public Library of Science (PLoS) |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Induced pluripotent stem (iPS) cells have an enormous potential for physiological studies. A novel protocol was developed combining the derivation of iPS from peripheral blood with an optimized directed differentiation to cardiomyocytes and a subsequent metabolic selection. The human iPS cells were retrovirally dedifferentiated from activated T cells. The subsequent optimized directed differentiation protocol yielded 30-45% cardiomyocytes at day 16 of differentiation. The derived cardiomyocytes expressed appropriate structural markers like cardiac troponin T, α-actinin and myosin light chain 2 (MLC2V). In a subsequent metabolic selection with lactate, the cardiomyocytes content could be increased to more than 90%. Loss of cardiomyocytes during metabolic selection were less than 50%, whereas alternative surface antibody-based selection procedures resulted in loss of up to 80% of cardiomyocytes. Electrophysiological characterization confirmed the typical cardiac features and the presence of ventricular, atrial and nodal-like action potentials within the derived cardiomyocyte population. Our combined and optimized protocol is highly robust and applicable for scalable cardiac differentiation. It provides a simple and cost-efficient method without expensive equipment for generating large numbers of highly purified, functional cardiomyocytes. It will further enhance the applicability of iPS cell-derived cardiomyocytes for disease modeling, drug discovery, and regenerative medicine. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Conceived and designed the experiments: MFS MEZ KS SW CH. Performed the experiments: MFS MEZ NJ MK MD SW. Analyzed the data: MFS MEZ NJ MD SW. Contributed reagents/materials/analysis tools: KS LSM UH AB MF CH. Wrote the paper: MFS MEZ SW CH. Competing Interests: The authors have declared that no competing interests exist. These authors also contributed equally to this work. Current address: Department of Genetic Epidemiology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany Current address: Sartorius Stedim Biotech GmbH, R&D Cell Culture Technologies, Göttingen, Germany Current address: DZHK (German Centre for Cardiovascular Research), partnersite Munich Heart Alliance, Munich, Germany Current address: Deutsches Herzzentrum München, Technische Universität München, Munich, Germany |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0126596 |